Associate Professor and Associate Program Director of the Saint Louis University Family Medicine Residency.
Assistant Professor and Program Director of the Saint Louis University Family Medicine Residency. Both are in the Department of Family and Community Medicine, Saint Louis University School of Medicine, St. Louis, Missouri.
Mo Med. 2022 May-Jun;119(3):213-218.
Bipolar Affective Disorder (BPAD) is frequently encountered in the primary care office and must be considered in the differential diagnosis of all patients with mood dysregulation. Appreciation for the range of bipolar illness has evolved in recent years, and the overlap of bipolar illness with trauma-based diagnosis such as Post-Traumatic Stress Disorder (PTSD) and Borderline Personality Disorder must be considered. Treatment of BPAD is divided into manic, depressive, and maintenance phases, each with different pharmacologic considerations. First line agents for the acute manic phase include lithium, valproic acid, and second generation antipsychotics (SGAs). First line agents for depressive phase include lamotrigine, lithium, and the SGAs lurasidone and quetiapine. For bipolar maintenance therapy, lamotrigine, valproic acid, and lithium are first line options. Finally, nonpharmacologic interventions including psychoeducation can be extremely helpful for patients and their families to successfully participate in the management of their disease.
双相情感障碍(BPAD)在初级保健诊所中经常遇到,必须在所有情绪失调患者的鉴别诊断中考虑。近年来,人们对双相情感障碍的认识已经发展,必须考虑到双相情感障碍与创伤相关的诊断(如创伤后应激障碍[PTSD]和边缘性人格障碍)之间的重叠。BPAD 的治疗分为躁狂、抑郁和维持三个阶段,每个阶段都有不同的药物考虑。急性躁狂期的一线药物包括锂、丙戊酸和第二代抗精神病药物(SGAs)。抑郁期的一线药物包括拉莫三嗪、锂和 SGA 类药物鲁拉西酮和喹硫平。对于双相情感障碍的维持治疗,拉莫三嗪、丙戊酸和锂是一线选择。最后,非药物干预措施,包括心理教育,对患者及其家属成功参与疾病管理非常有帮助。